Zydus to Initiate Clinical Study of Desidustat in Patients with Chemotherapy-Induced Anemia (CIA)

 Zydus to Initiate Clinical Study of Desidustat in Patients with Chemotherapy-Induced Anemia (CIA)

Zydus Signs a License Agreement with XOMA to Advance IL-2- Based Immuno-Oncology Therapy

Shots:

  • Zydus has received the US FDA’s approval to initiate clinical trials of Desidustat in CIA. The company has initiated two P-III studies of desidustat
  • The P-III DREAM-ND (NCT04012957) study is being conducted in 588 CKD patients not-on-dialysis while the P-III DREAM-D is being conducted in 392 CKD patients on dialysis (NCT04215120)
  • The therapy met its 1EPs in P-II study and demonstrated a good safety profile while P-I trials were earlier completed in Australia. Desidustat (PO) is a novel hypoxia-inducible factor prolyl hydroxylase inhibitor, currently undergoing P-III development for anemia in CKD patients, and P-II(b) studies for management of COVID-19 patients

Click here to read full press release/ article | Ref: Zydus | Image: Twitter

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post